We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £691,497
planarTECH is an engineering company founded in 2014 as a provider of process equipment for the growth and characterisation of graphene and other emerging 2D materials. Its core product line is the planarGROW Chemical Vapor (CVD) system. The company has the ability to deliver scalable production systems that allow lower-cost production of graphene in comparison to other options currently available in the market. Moreover, from 2014 to 2019, the company’s cumulative revenues exceeded £5 million. The company's products have been installed and used by faculties and students at prestigious universities like Stanford University (USA), IIT- Bombay (India), Deakin University (Australia), and many others. From the investment, the company will utilise 45% as working capital, 30% in Capital Expenditures (CAPEX), 15% in R&D and 10% in hiring additional staff.

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £425,061
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Pawprint is a behavioural change platform that is on a mission to fight climate change. The platform allows people to measure, understand and reduce their carbon footprint, and fight ‘climate change’ by giving people bite-sized chunks to focus on. It aims to be the middleman, helping brands reach and understand their audience by offering these brands personalised challenges to help their reduce carbon footprint. The market for behavioural change platforms is slowly gaining solid traction with established brands such as Fitbit, Strava, and Calm. Pawprint aims to capitalise on this collective concern and deliver services that help mitigate those concerns.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £352,440
Exchange Train (ET) is an online comparison website where property solicitors have 24 hours to bid for the home-movers custom in real-time. ET argues that there are over 19,000 property solicitors in the UK each providing a different quality of service, price, and turnaround time. ET aims to overhaul this process. Its portal locates the top solicitors for the customer’s specific transaction, based not only on price but what's most important to the customer. ET has had over 10,000 visitors, generated over 650 quotes, and signed up 22 solicitors on its portal, to date. The company has also featured in TodaysConveyancer, The Property Industry Eye, and The Negotiator Magazine. It will use 30% of the investment towards accelerating website development, 36% towards boosting Public Relations (PR), 18% towards enhancing Google Ads and social media, and 16% towards growing business operations.

Pitch Rated

41%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £123,900
nu:move Group is an award-winning Hybrid nationwide online estate agency. The company offers its customers a simple, online process to sell and let their property. The business is built on an ethos of modern innovation and traditional values by blending online and high street estate agency services seamlessly. The company offers a full set of estate agency services and affordable sales packages. nu:move Group has marketed more than 10,000 properties globally that are worth £3Bn and has received a 5 Star Trust Pilot Rating. The company has won The Negotiator 'Hybrid Estate Agent of the Year Award 2019.' 40% of the investment will be used for brand awareness, 30% for technology, 20% for franchise network training and expansion, and 105 for staffing at nu:move HQ.

Pitch Rated

40%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £153,342
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Cell Guidance Systems is developing a technology called PODS (Polyhedrin Delivery System) PODS allow them to deliver therapeutic proteins accurately and over long periods of time. PODS enable proteins to treat diseases, such as Parkinson’s disease and osteoarthritis.
days to go: Expired investment: £836,370
FloatWind manufactures mass-produced floating offshore wind turbines. It seeks to disrupt the £20 billion offshore wind energy market. The company argues that conventional offshore wind farms, installed at sea, use expensive and slow installation methods that are also dangerous to the marine environment. It further stresses that the high cost of installation is often borne by the consumer. FloatWind asserts that its business model is different. The company claims to build its products on land and then floats its ready-to-float turbines out to sea. The company points out that this reduces environmental damage, substantially reduces costs, and makes offshore wind energy cheaper. FloatWind was selected for a 6-month UK Innovate Edge business mentoring programme and appeared for SetSquared Business Mentoring Seminar in May 2021. The company has 3,000+ followers on LinkedIn. FloatWind states it will use the investment for product development, expanding its team, IP protection, promoting marketing and PR, and boosting its manufacturing capabilities.
days to go: Expired investment: £311,497
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph